{
    "clinical_study": {
        "@rank": "109190", 
        "arm_group": [
            {
                "arm_group_label": "Seretide Evohaler", 
                "arm_group_type": "Active Comparator", 
                "description": "Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Seretide Evohaler, Allen & Hanburys, UK)\nStrength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
            }, 
            {
                "arm_group_label": "Salmeterol xinafoate and Fluticasone propionate HFA pMDI", 
                "arm_group_type": "Experimental", 
                "description": "Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Cipla Ltd., India)\nStrength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will be conducted as a randomized, double blind, double dummy two period\n      crossover study in stable asthma patients. A total of 16 stable asthma patients treated in\n      accordance with the Global Initiative for Asthma (GINA) guidelines, will be included.\n\n      Objectives:\n\n        -  The primary objective of this study is to evaluate the effect of both the study drugs\n           under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate\n           the particle deposition in the lungs using  Computational Fluid Dynamic (CFD)\n\n        -  The secondary objectives  are to assess the effect of both the study drugs on lung\n           function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking\n           Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog\n           Scale (VAS) dyspnea). Furthermore the safety of the 2 products under investigation will\n           be evaluated through monitoring of adverse events (AEs) throughout the study."
        }, 
        "brief_title": "Compare the Effects of Seretide\u00ae Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patient \u2265 18 years old\n\n          -  Written informed consent obtained\n\n          -  Patient with a documented diagnosis of asthma according to the GINA guidelines\n\n          -  Patient with a co-operative attitude and ability to be trained to correctly use the\n             pMDI\n\n          -  Female patient of childbearing potential who confirm that a contraception method was\n             used at least 14 days before visit 1 and will continue to use a contraception method\n             during the study\n\n          -  Patient must be stable and treated in accordance with the GINA guidelines\n\n          -  Patient must be a non-smoker or ex-smoker who have stopped smoking at least 1 year\n             prior to  visit 1 and has a smoking history of < 10 pack years\n\n          -  Patient must be able to understand and complete the protocol requirements,\n             instructions, questionnaires and protocol-stated restrictions\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating female\n\n          -  Unstable patient who developed an exacerbation during the last 8 weeks\n\n          -  Patient with upper or lower airways infection\n\n          -  Patient unable to carry out pulmonary function testing\n\n          -  Patient with an uncontrolled disease or any condition that might, in the judgement of\n             the investigator, place the patient at undue risk or potentially compromise the\n             results or interpretation of the study\n\n          -  Patient with cancer or any other chronic disease with poor prognosis and /or\n             affecting patient status\n\n          -  Patient with allergy, sensitivity or intolerance to study drugs and/or study drug\n             formulation ingredients\n\n          -  Patient unlikely to comply with the protocol or unable to understand the nature,\n             scope and possible consequences of the study\n\n          -  Patient who received oral corticosteroids within the last 4 weeks prior to visit 1\n\n          -  Patient who received any investigational new drug within the last 4 weeks prior to\n             visit 1 or twice the duration of the biological effect of any drug (whichever is\n             longer)\n\n          -  Patient with a history of alcohol or substance abuse that in the opinion of the\n             investigator may be of clinical significance\n\n          -  Patient who has undergone major surgery in the last 12 weeks before the visit 1 or\n             has planned to undergo a major surgery before the end of the trial\n\n          -  Patient with diagnosis of chronic obstructive pulmonary disease (COPD)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795664", 
            "org_study_id": "FLUI-2012-94", 
            "secondary_id": [
                "2012-005789-36", 
                "E-RES/12/12-Q13"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Seretide Evohaler", 
                    "Salmeterol xinafoate and Fluticasone propionate HFA pMDI"
                ], 
                "description": "CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose", 
                "intervention_name": "Functional Respiratory Imaging", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Salmeterol xinafoate and Fluticasone propionate HFA pMDI", 
                "description": "Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg\nAt visit 2 or visit 3 (cross-over design)", 
                "intervention_name": "Salmeterol xinafoate and Fluticasone propionate HFA pMDI", 
                "intervention_type": "Drug", 
                "other_name": "Test product"
            }, 
            {
                "arm_group_label": "Seretide Evohaler", 
                "description": "Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg\nAt visit 2 or visit 3 (cross-over design)", 
                "intervention_name": "Seretide Evohaler", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Reference product", 
                    "Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI"
                ]
            }, 
            {
                "arm_group_label": "Seretide Evohaler", 
                "description": "Single dose of 2 puffs\nTo ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day.", 
                "intervention_name": "Placebo of Test product", 
                "intervention_type": "Drug", 
                "other_name": "Placebo inhaler containing HFA propellant resembling the test active inhaler"
            }, 
            {
                "arm_group_label": "Salmeterol xinafoate and Fluticasone propionate HFA pMDI", 
                "description": "Single dose of 2 puffs\nTo ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day.", 
                "intervention_name": "Placebo of Reference product", 
                "intervention_type": "Drug", 
                "other_name": "Placebo inhaler containing HFA propellant resembling the reference active inhaler"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Salmeterol", 
                "Albuterol", 
                "Fluticasone", 
                "Fluticasone, salmeterol drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Asthma", 
            "Salmeterol xinafoate and Fluticasone propionate", 
            "Seretide Evohaler", 
            "Functional Respiratory Imaging", 
            "Computational Fluid Dynamic"
        ], 
        "lastchanged_date": "September 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Edegem", 
                    "country": "Belgium", 
                    "state": "Antwerp", 
                    "zip": "2650"
                }, 
                "name": "Antwerp University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double Blind, Double Dummy, Randomized, Two Way Cross-over Study to Compare the Effects of Seretide\u00ae Evohaler (Supplied by Allen & Hanburys, UK) and a Generic Salmeterol/Fluticasone HFA pMDI (Manufactured by Cipla Ltd, India) on Functional Respiratory Imaging Parameters in Asthmatic Patients.", 
        "overall_official": {
            "affiliation": "University Hospital, Antwerp", 
            "last_name": "Wilfried De Backer, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using  Computational Fluid Dynamic (CFD)", 
                "measure": "Total airway volume", 
                "safety_issue": "No", 
                "time_frame": "At visit 2 (= 7-11 days after visit 1)"
            }, 
            {
                "description": "The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using  Computational Fluid Dynamic (CFD)", 
                "measure": "The number of deposited particles per pre-defined airway section", 
                "safety_issue": "No", 
                "time_frame": "At visit 2 (= 7-11 days after visit 1)"
            }, 
            {
                "description": "The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using  Computational Fluid Dynamic (CFD)", 
                "measure": "Total airway resistance", 
                "safety_issue": "No", 
                "time_frame": "At visit 2 (= 7-11 days after visit 1)"
            }, 
            {
                "description": "The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using  Computational Fluid Dynamic (CFD)", 
                "measure": "Total airway volume", 
                "safety_issue": "No", 
                "time_frame": "At visit 3 (= 3-7 days after visit 2)"
            }, 
            {
                "description": "The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using  Computational Fluid Dynamic (CFD)", 
                "measure": "The number of deposited particles per pre-defined airway section", 
                "safety_issue": "No", 
                "time_frame": "At visit 3 (= 3-7 days after visit 2)"
            }, 
            {
                "description": "The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using  Computational Fluid Dynamic (CFD)", 
                "measure": "Total airway resistance", 
                "safety_issue": "No", 
                "time_frame": "At visit 3 (= 3-7 days after visit 2)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795664"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The secondary objectives  are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).", 
                "measure": "Lung function tests (spirometry, body plethysmography)", 
                "safety_issue": "No", 
                "time_frame": "At visit 2 (= 7-11 days after visit 1)"
            }, 
            {
                "description": "The secondary objectives  are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).", 
                "measure": "Exercise capacity (6 minutes walking test)", 
                "safety_issue": "No", 
                "time_frame": "At visit 2 (= 7-11 days after visit 1)"
            }, 
            {
                "description": "The secondary objectives  are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).", 
                "measure": "Dyspnea (BORG CR 10 scale and VAS dyspnea)", 
                "safety_issue": "No", 
                "time_frame": "At visit 2 (= 7-11 days after visit 1)"
            }, 
            {
                "description": "The safety of the 2 products under investigation will be evaluated through monitoring of adverse events (AEs) throughout the study.", 
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From visit 1 until visit 4 = timeperiod of 3 \u00e0 4 weeks"
            }, 
            {
                "description": "The secondary objectives  are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).", 
                "measure": "Lung function tests (spirometry, body plethysmography)", 
                "safety_issue": "No", 
                "time_frame": "At visit 3 (= 3-7 days after visit 2)"
            }, 
            {
                "description": "The secondary objectives  are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).", 
                "measure": "Exercise capacity (6 minutes walking test)", 
                "safety_issue": "No", 
                "time_frame": "At visit 3 (= 3-7 days after visit 2)"
            }, 
            {
                "description": "The secondary objectives  are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).", 
                "measure": "Dyspnea (BORG CR 10 scale and VAS dyspnea)", 
                "safety_issue": "No", 
                "time_frame": "At visit 3 (= 3-7 days after visit 2)"
            }
        ], 
        "source": "FluidDA nv", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "FluidDA nv", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}